Update with respect to a post from last July, a year ago.......
>> I can't find details of the CIST/Techne agreement, other than Techne (R&D Systems)
has "exclusive co-marketing rights". This _could_ mean that CIST retains rights to
license the assay for europe and asia. :-)
Another event to watch for..... to my knowledge, the Genzyme agreement expires in
7/98. GENZ will need to obtain IL-1 and kits beyond this date. We should therefore
get an indication, in a year if not sooner, of the strength/scope of the PeproTech license.
I still feel that GENZ would be crazy not to consider the fit. And, if there is any viability
at all to the periodontal assay, Techne will of course be interested. <<
We now know that Techne actually purchased the GENZ reagent's business. Since GENZ sourced many materials from PeproTech, I consider this to be a push. Galton, in the midst of his brilliance, had already sold his leverage.
We also know, now, that there was no viability to the periodontal assay. And, given the anemic sales in the past year, I guess we have our indication of the "strength/scope of the PeproTech license". |
